ORIL is a public, unlisted Australian company that has identified and developed a family of plant-based anti-cancer compounds. The Company has an internationally recognised Board, management and advisory teams with a balance of skills, experience and substantial track records in science and business in the biotech and pharma industry.

ORIL has developed a unique anticancer drug with outstanding market potential. The platform technology is based on a first-in-class mode of action that targets the cancer cell membrane. The current focus is on the treatment of cancer but with potential for other therapeutic applications.